Turn Therapeutics Inc. (TTRX)
NASDAQ: TTRX · Real-Time Price · USD
4.050
+0.030 (0.75%)
May 15, 2026, 4:00 PM EDT - Market closed
Turn Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A novel polymer-based ointment targeting IL-36/IL-31 is in phase II trials for moderate to severe eczema, with interim and top-line data expected in Q2 2026. The company also advances a phase III-ready onychomycosis drug and explores additional dermatology indications, supported by strong safety data and patent protection.
-
The company is advancing a novel topical therapy for moderate to severe eczema, with a large phase II trial underway and interim results expected in Q2 2026. Its lead asset, GX-03, shows strong safety and efficacy, with plans for phase III trials in both eczema and onychomycosis.